STOCKS TELEGRAPH

Tag: CVAC

  • Here is why CureVac N.V. (CVAC) stock plunged in the after-hours on Wednesday?

    Here is why CureVac N.V. (CVAC) stock plunged in the after-hours on Wednesday?

    CureVac N.V. (CVAC) shares dipped 8.82% in after-hours on Wednesday, June 30, 2021, and closed at $67.00 per share. Earlier in the morning session, CVAC’s stock gained 8.92% to close Wednesday’s normal trading session at $73.48. CVAC shares have moved up by 29.12% in the past week. Over the past three months, the stock has lost 19.66%, while over the past six months, it has shed 13.42%.

    Let’s see why CVAC stock faced negativity in the after-hours on Wednesday?

    Low efficacy recorded in the final trial of COVID-19 CVnCoV vaccine

    On June 30, 2021, CureVac N.V. announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

    CVnCoV demonstrated an overall vaccine efficacy of only 48%against COVID-19 disease of any severity, including single non-respiratory mild symptoms.

    The efficacy of 53% was achieved among participants in the age group of 18 to 60.

    In the same age group, CVnCoV provided 100% protection (vaccine 0 vs. 6 placebo) against hospitalization or death. The data confirm the favourable safety profile of CVnCoV in all age groups.

    New appointments

    On June 30, 2021, CureVac N.V. appointed Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021.

    Dr Florian von der Mülbe, co-founder and Chief Production Officer of the company will also now focus his extensive production expertise exclusively on the expansion and accelerated development of The RNA Printer(R).

    On June 2, 2021, CureVac N.V. appointed Klaus Edvardsen, MD, Ph.D., as Chief Development Officer. The appointment of Dr. Edvardsen will take effect on August 1, 2021.

    Supervisory Board Update

    On June 23, 2021, CureVac N.V. announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board.

    Recent financial results announcement

    On May 26, 2021, CureVac N.V released its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • CureVac reported revenue of €10.0 million for the first three months of 2021 compared to revenue of €3.1 million for the same period in 2020.
    • The company suffered from an operating loss of €115.8 million for the first three months of 2021 compared to an operating loss of €23.2 million for the same period in 2020.
    • The cost of sales and other operating expenses were €26.3 million for Q1 2021 compared to €125.8 million in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of€1,497 million compared to €1,323 million as of December 31, 2020. 

    Conclusion

    The CVAC stock plummeted after the company announced that its Covid-19 vaccine shows 48% efficacy in the final analysis. The CVAC stock can further go down on Thursday as well because it’s a major setback for the company. 

  • Why CureVac BV (CVAC) stock plummeted on Wednesday after an important announcement?

    Why CureVac BV (CVAC) stock plummeted on Wednesday after an important announcement?

    CureVac N.V. (CVAC) shares plunged 45.67% in the after-hours on Wednesday, June 16, 2021, and close the session at $51.50 per share. Earlier, in the morning session, CVAC’s stock lost 3.47% to close Wednesday’s session at $94.79 per share. CVAC shares have moved down by 10.34% in the past week. Over the past three months, the stock has gained 0.53%, while over the past six months, it has shed 21.70%.

    Let’s try to find out why CVAC stock lost significantly on Wednesday?

    Update on Phase 2b/3 Trial ofCOVID-19 VaccineCVnCoV

    On June 16, 2021, CureVac N.V. announced the results of the second interim analysis of its international pivotal Phase 2b/3 study in approximately 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV.

    CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. The study is continuing to the final analysis and the totality of the data will be assessed for the most appropriate regulatory pathway.

    Earlier, on June 1, 2021, the company reported that the independent Data Safety Monitoring Board (DSMB) confirmed that the phase IIb/III study (HERALD) for CVnCoV has passed the first interim analysis in 59 adjudicated COVID-19 cases with no safety concerns.

    New appointment

    On June 2, 2021, CureVac N.V. appointed Klaus Edvardsen, MD, Ph.D., as Chief Development Officer. The appointment of Dr Edvardsen will take effect on August 1, 2021.

    Recent financial results announcement

    On May 26, 2021, CureVac N.V released its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • CureVac reported revenue of €10.0 million for the first three months of 2021compared to revenue of €3.1 million for the same period in 2020.
    • The company suffered from an operating loss of €115.8 million for the first three months of 2021 compared to an operating loss of €23.2 million for the same period in 2020.
    • The cost of sales and other operating expenses were €26.3 million for Q1 2021 compared to €125.8 million in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of€1,497 million compared to €1,323 millionas of December 31, 2020. 

    Conclusion

    The CVAC stock plummeted after the company announced that its Covid-19 vaccine shows 47% efficacy against Coronavirus variants. The CVAC stock can further go down on Thursday as well.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.